title: Amide N-glucuronidation of MaxiPost catalyzed by UDP-glucuronosyltransferase 2B7 in humans.
abstract: MaxiPost [(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one), or BMS-204352)] is a potent and specific maxi-K channel opener for potential use to treat stroke. This article describes structural characterization of a major human N-glucuronide metabolite of BMS-204352 and identification of the enzyme responsible for the N-glucuronidation reaction. After intravenous administrations of [(14)C]BMS-204352 (10 mg, 50 microCi) to eight healthy human subjects, one major metabolite M representing an average of 17% of the radioactive dose was excreted in pooled urine collected over 0 to 336 h after dosing. A major biliary metabolite of dogs dosed with [(14)C]BMS-204352 (5 mg/kg), which represented about 33% of the dose, has the same retention time and the same tandem mass spectrometry fragmentation pattern as the human urinary metabolite M. Four hundred fifty micrograms of the metabolite was isolated from the dog bile and analyzed by NMR. Long-range (1)H-(13)C NMR experimentation indicated that the glucuronic acid moiety was at the nitrogen site. The N-glucuronide of BMS-204352 was stable up to 24 h at 37 degrees C in the incubations at different pH values (3.0, 7.4, and 9.0) and with glucuronidases from Escherichia coli and Helix pomatia. Of the seven human UDP-glucuronosyltransferases (UGT) isozymes (1A1, 1A3, 1A4, 1A6, 1A7, 1A10, and 2B7) tested, only UGT2B7 produced metabolite M. UGT2B7-catalyzed N-glucuronidation of BMS-204352 exhibited Michaelis-Menten kinetics with a K(m) of 14.2 microM and V(max) of 0.29 nmol/min. mg of protein. Collectively, these results suggest that amide N-glucuronidation, a major elimination pathway of MaxiPost, is catalyzed by UGT2B7 in humans. This N-glucuronide represents a fully characterized amide N-glucuronide, and glucuronidation at the nitrogen represents a newly identified conjugation reaction for UGT2B7.
authors.affiliation: Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research Institute, Route 206 and Province-Line Road, Princeton, NJ 08543, USA. donglu.zhang@bms.com
authors.forename: Donglu
authors.initials: D
authors.lastname: Zhang
authors.forename: Weiping
authors.initials: W
authors.lastname: Zhao
authors.forename: Vikram A
authors.initials: VA
authors.lastname: Roongta
authors.forename: James G
authors.initials: JG
authors.lastname: Mitroka
authors.forename: Lewis J
authors.initials: LJ
authors.lastname: Klunk
authors.forename: Mingshe
authors.initials: M
authors.lastname: Zhu
mesh_terms: D000577:Amides / Q000378:metabolism*; D000818:Animals; D002384:Catalysis; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D020719:Glucuronides / Q000378:metabolism*; D014453:Glucuronosyltransferase / Q000378:metabolism*; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000378:metabolism*; D051036:Large-Conductance Calcium-Activated Potassium Channels; D008297:Male; D024681:Potassium Channels, Calcium-Activated / Q000819:agonists / Q000378:metabolism
chemical_list: D000577:Amides; C424388:BMS204352; D020719:Glucuronides; D007211:Indoles; D051036:Large-Conductance Calcium-Activated Potassium Channels; D024681:Potassium Channels, Calcium-Activated; C491474:UGT2B7 protein, human; D014453:Glucuronosyltransferase